The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.

In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months.

Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership

Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ductus arteriosus in premature infants

Unique cell-impermeable1 design extends life-saving treatment for dialysis patients.

WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial

Versatile analog device offers fast inflation and ease of use, streamlining patient care

Joe Wright Appointed President, Expands Deep Bench of Leadership Team Talent; Supports “Continued Growth Initiatives” Program.

New products broaden Merit’s leadership in embolotherapy.

First Patient Enrolled in Merit Medical’s MOTION Study

Merit Medical Announces Process for Chief Executive Officer Succession Planning